HBOT Conversations:
Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy
Subscribe. Join the discussion. Share the hope.
Listen to or Watch the HBOT Conversations Podcast
Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:
Watch the HBOT Conversations Podcast
Subscribe Now, It’s Free !
Recent HBOT News
Changes in vasomotion–effect of hyperbaric oxygen in patients with diabetes Type 2.
Abstract: To investigate vasomotion in diabetic patients who underwent sessions of hyperbaric oxygen (HBO2) therapy. Seventy-one patients with diabetes Type 2 and lower-extremity neuropathy were enrolled in a prospective matched case-control study. A total of 39...
Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?
Abstract: Tumor hypoxia is a major cause for failure of therapy in patients with inoperable head and neck cancers. Various anti-hypoxic treatment strategies (e.g. hyperbaric oxygenation, hypoxic cell sensitizers) have been tested in clinical trials in head and neck...
Clinical Trial – Ondansetron vs Ondansetron Plus Dexamethasone for Relieving Intrathecal Morphine Side Effects After C-section
Background: Common adverse side effects related to the use of neuraxial opioids in the
obstetric population include nausea, vomiting, and pruritus. Serotonin (5-HT3) receptor
antagonists, in particular ondansetron, have been identified as possible antipruritic agents.
It was reported that dexamethasone plus ondansetron is more effective than ondansetron for
prevention of postoperative nausea and vomiting but no additional effect on treating
pruritus.
Objectives: The purpose of this study is to compare the effect of prophylactic ondansetron
versus ondansetron plus dexamethasone after cesarean section on pruritus and postoperative
nausea and vomiting (PONV).
Methods: A prospective randomized double blind study that will be conducted between June 2016
and June 2017. Patients will be randomly allocated into two groups. The first group will
receive 4 mg intravenous (IV) ondansetron while the other group will receive 4 mg IV
ondansetron plus 8 mg dexamethasone.